RGLS | Regulus Therapeutics Inc. |
Pharmaceutical Preparations |
Book value per $ invested | $ 3.11 |
Leverage | 5.70% |
Market Cap | $ 31.5m |
PE | 0.00 |
Dividend Yield | 0.00% |
Profit | $ -35.1m |
Margin | 15169.19% |
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of drugs that target microRNAs to treat a variety of diseases in the United States. The company is headquartered in San Diego, California.